The relationship between TA-DAS28(CRP) tertiles and changes in radiographic scores
| 52 Weeks | 104 Weeks | |||
|---|---|---|---|---|
| Outcome | Median (TA-DAS28(CRP) T1/T2/T3)* | p Value† | Median (TA-DAS28(CRP) T1/T2/T3)* | p Value† |
| Change in JE | ||||
| ADA+MTX | 0.00/0.00/0.00 | 0.06 | 0.00/0.25/0.00 | 0.31 |
| ADA | 0.00/0.25/0.50 | <0.001 | 0.25/0.50/1.00 | <0.001 |
| MTX | 0.00/1.50/2.00 | 0.01 | 0.00/0.75/2.50 | <0.001 |
| Change in JSN | ||||
| ADA+MTX | 0.00/0.00/0.00 | 0.63 | 0.00/0.00/0.25 | 0.14 |
| ADA | 0.00/0.00/1.00 | <0.001 | 0.00/0.00/1.00 | <0.001 |
| MTX | 0.00/0.00/0.75 | 0.02 | 0.00/0.50/1.00 | 0.02 |
*Tertiles originate from figures 1 and 2.
†p Value from the analysis of variance on the van der Waerden normal scores is to test for equivalence across tertiles. Median values across the tertiles are indicative of trends.
ADA, adalimumab; CRP, C-reactive protein; JE, joint erosion; JSN, joint space narrowing; MTX, methotrexate; TA-DAS28(CRP), time averaged 28-joint disease activity score with C-reactive protein; T1, tertile 1; T2, tertile 2; T3, tertile 3.